Related Experiment Videos
Screening assay for promigratory/antimigratory compounds
W L Rust1, J L Huff, G E Plopper
1Department of Biological Sciences, University of Nevada, Las Vegas 89154, USA.
Abstract:
Large-scale screening strategies aimed at finding anticancer drugs traditionally focus on identifying cytotoxic compounds that attack actively dividing cells. Because progression to malignancy involves acquisition of an aggressively invasive phenotype in addition to hyperproliferation, simple and effective screening strategies for finding compounds that target the invasive aspects of cancer progression may prove valuable for identifying alternative and preventative cancer therapies. Here, we describe a fluorescence-based automated assay for identifying antimigratory compounds, with the ability to discern cytotoxic from noncytotoxic modes of action. With this assay, we analyzed the effects of two drugs on tumorigenic (MDA-MB-435) and nontumorigenic (MCF-10A) human breast cell lines. We chose to compare carboxyamidotriazole (CAI), an experimental compound shown to inhibit migration of various cell types, with tamoxifen, a common preventative and therapeutic anticancer compound. Our assay demonstrated that both these compounds inhibit migration at sublethal concentrations. Furthermore, CAI was more effective than tamoxifen at inhibiting chemotactic and haptotactic migration of both cell lines at all concentrations tested.
Insights
This study introduces a new assay to find anticancer drugs that stop cancer cell migration. The assay found that carboxyamidotriazole (CAI) is more effective than tamoxifen at inhibiting cancer cell movement.
Area of Science:
- Oncology
- Cell Biology
- Drug Discovery
Background:
- Traditional anticancer drug screening targets cell proliferation.
- Cancer progression involves increased invasiveness, necessitating new therapeutic strategies.
- Targeting cancer cell migration offers potential for alternative and preventative cancer therapies.
Purpose of the Study:
- To develop and validate a fluorescence-based automated assay for identifying antimigratory compounds.
- To differentiate between cytotoxic and non-cytotoxic mechanisms of action in drug screening.
- To compare the antimigratory efficacy of carboxyamidotriazole (CAI) and tamoxifen in human breast cell lines.
Main Methods:
- Development of a fluorescence-based automated assay for assessing cell migration.
- Testing of the assay on tumorigenic (MDA-MB-435) and nontumorigenic (MCF-10A) human breast cell lines.
- Comparative analysis of carboxyamidotriazole (CAI) and tamoxifen's effects on chemotactic and haptotactic migration at various concentrations.
Main Results:
- The developed assay successfully identified compounds that inhibit cell migration.
- Both CAI and tamoxifen demonstrated antimigratory effects at sublethal concentrations.
- CAI exhibited superior inhibition of both chemotactic and haptotactic migration compared to tamoxifen across all tested concentrations.
Conclusions:
- A novel automated assay enables effective screening for antimigratory anticancer compounds.
- CAI shows significant potential as an antimigratory agent, outperforming tamoxifen in vitro.
- This approach may lead to the development of novel preventative and therapeutic strategies targeting cancer invasion.